Beskid G, Fallat V, Siebelist J, Durkin J W, Lipschitz E R, McGarry D H
J Clin Microbiol. 1987 Jul;25(7):1186-90. doi: 10.1128/jcm.25.7.1186-1190.1987.
The activity of Ro 19-5247 (the active metabolite of the oral cephalosporin Ro 19-5248 [T-2588]) was compared with that of five orally active agents against a total of 331 bacterial strains. Ro 19-5247 was more active in vitro than amoxicillin, amoxicillin-clavulanate, cefaclor, cefuroxime, and cephalexin against members of the family Enterobacteriaceae. Amoxicillin-clavulanate and amoxicillin overall were more active than the other four agents against staphylococci. Ro 19-5247, amoxicillin-clavulanate, amoxicillin, and cefuroxime were equally active against nonenterococcal streptococci and more active than cefaclor and cephalexin. All six agents showed little or no activity against nonfermentative gram-negative bacteria. Against Streptococcus (Enterococcus) faecalis, only amoxicillin and amoxicillin-clavulanate were active. The interpretive criteria for in vitro susceptibility testing with 10- and 30-micrograms Ro 19-5247 disks were established by regression analysis to correlate the inhibitory zone sizes and MICs for the bacterial isolates. The suggested tentative zone size breakpoints for the 10-micrograms disk are as follows: susceptible, greater than or equal to 22 mm (MIC, less than or equal to 2 micrograms/ml); moderately susceptible, 20 to 21 mm (MIC, 4 micrograms/ml); and resistant, less than or equal to 19 mm (MIC, greater than or equal to 8 micrograms/ml).
将口服头孢菌素Ro 19-5248(T-2588)的活性代谢产物Ro 19-5247与五种口服活性药物对总共331株细菌的活性进行了比较。Ro 19-5247在体外对肠杆菌科细菌的活性比阿莫西林、阿莫西林-克拉维酸、头孢克洛、头孢呋辛和头孢氨苄更强。阿莫西林-克拉维酸和阿莫西林总体上对葡萄球菌的活性比其他四种药物更强。Ro 19-5247、阿莫西林-克拉维酸、阿莫西林和头孢呋辛对非肠球菌性链球菌的活性相同,且比头孢克洛和头孢氨苄更强。所有六种药物对非发酵革兰氏阴性菌几乎没有或没有活性。对于粪肠球菌,只有阿莫西林和阿莫西林-克拉维酸有活性。通过回归分析确定了用含10微克和30微克Ro 19-5247的纸片进行体外药敏试验的解释标准,以关联细菌分离株的抑菌圈大小和最低抑菌浓度。对于含10微克纸片,建议的暂定抑菌圈大小断点如下:敏感,大于或等于22毫米(最低抑菌浓度,小于或等于2微克/毫升);中度敏感,20至21毫米(最低抑菌浓度,4微克/毫升);耐药,小于或等于19毫米(最低抑菌浓度,大于或等于8微克/毫升)。